Characterization of the 4-(Benzothiazol-2-yl)phenylnitrenium Ion from a Putative Metabolite of a Model Antitumor Drug

被引:24
作者
Chakraborty, Mrinal [1 ]
Jin, Kyoung Joo [1 ]
Glover, Stephen A. [2 ]
Novak, Michael [1 ]
机构
[1] Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA
[2] Univ New England, Dept Chem, Sch Sci & Technol, Armidale, NSW 2351, Australia
关键词
ARYL-HYDROCARBON RECEPTOR; BREAST-CANCER CELLS; CORRESPONDING HYDROXAMIC ACID; AMYLOID-IMAGING AGENTS; IN-VITRO ANTITUMOR; BIOLOGICAL-PROPERTIES; AQUEOUS-SOLUTION; NITRENIUM IONS; CARCINOGENIC N-(4-BIPHENYLYL)HYDROXYLAMINE; 1-PHENYLETHYL DERIVATIVES;
D O I
10.1021/jo101275y
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The 4-(benzothiazol-2-yl)phenylnitrenium ion 11 is generated from hydrolysis or photolysis of O-acetoxy-N-(4-(benzothiazol-2-yl)phenyl)hydroxylamine 8, a model metabolite of 2-(4-aminophenyl)benzothiazole 1 and its ring-substituted derivatives that are being developed for a variety of medicinal applications, including antitumor, antibacterial, antifungal, and imaging agents. Previously, we showed that 11 had an aqueous solution lifetime of 530 ns, similar to the 560 ns lifetime of the 4-biphenylylnitrenium ion 12 derived from the well-known chemical carcinogen 4-aminobiphenyl. We now show that the analogy between these two cations extends well beyond their lifetimes. The initial product of hydration of 11 is the quinolimine 16, which can be detected as a long-lived reactive intermediate that hydrolyzes in a pH-dependent manner into the final hydrolysis product, the quinol 15. This hydrolysis behavior is equivalent to that previously described for a large number of ester metabolites of carcinogenic arylamines, including 4-aminobiphenyl. The major azide trapping product (90% of azide products) of 11, 20, is generated by substitution on the carbons ortho to the nitrenium ion center of 11. This product is a direct analogue of the major azide adducts, such as 22, generated from trapping of the nitrenium ions of carcinogenic arylamines. The azide/solvent selectivity for 11, k(az)/k(s), is also nearly equivalent to that of 12. A minor product of the reaction of 11 with N-3(-), 21, contains no azide functionality but may be generated by a process in which N-3(-) attacks 11 at the nitrenium ion center with loss of N-2 to generate a diazene 25 that subsequently decomposes into 21 with loss of another N2. The adduct derived from attack of 2'-deoxyguanosine (d-G) on 11, 28, is a familiar C-8 adduct of the type generated from the reaction of d-G with a wide variety of arylnitrenium ions derived from carcinogenic arylamines. The rate constant for reaction of d-G with 11, k(d-G), is very similar to that observed for the reaction of d-G with 12. The similar lifetimes and chemical reactivities of 11 and 12 can be rationalized by B3LYP/6-31G(d) calculations on the two ions that show that they are of nearly equivalent stability relative to their respective hydration products. The calculations also help to rationalize the different regiochemistry observed for the reaction of N-3(-) with 11 and its oxenium ion analogue, 13. Since 8 is the likely active metabolite of 1 and a significant number of derivatives of 1 are being developed as pharmaceutical agents, the similarity of the chemistry of 11 to that of carcinogenic arylnitrenium ions is of considerable importance. Consideration should be given to this chemistry in continued development of pharmaceuticals containing the 2-(4-aminophenyl)benzothiazole moiety.
引用
收藏
页码:5296 / 5304
页数:9
相关论文
共 69 条
  • [1] Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648)
    Aiello, Stefania
    Wells, Geoffrey
    Stone, Erica L.
    Kadri, Hachemi
    Bazzi, Rana
    Bell, David R.
    Stevens, Malcolm F. G.
    Matthews, Charles S.
    Bradshaw, Tracey D.
    Westwell, Andrew D.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (16) : 5135 - 5139
  • [2] In vitro antitumor and antiviral activities of new benzothiazole and 1,3,4-oxadiazole-2-thione derivatives
    Akhtar, Tashfeen
    Hameed, Shahid
    Al-Masoudi, Najim A.
    Loddo, Roberta
    La Colla, Paolo
    [J]. ACTA PHARMACEUTICA, 2008, 58 (02) : 135 - 149
  • [3] [Anonymous], SPART 08 MAC VERS 1
  • [4] FORMATION AND PERSISTENCE OF ARYLAMINE DNA ADDUCTS INVIVO
    BELAND, FA
    KADLUBAR, FF
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 1985, 62 (OCT) : 19 - 30
  • [5] SYNTHESIS OF THE ULTIMATE HEPATOCARCINOGEN, 2-ACETYLAMINOFLUORENE N-SULFATE
    BELAND, FA
    MILLER, DW
    MITCHUM, RK
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1983, (01) : 30 - 31
  • [6] BOSOLD F, 1990, ANGEW CHEM, V102, P99
  • [7] The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate
    Bradshaw, TD
    Westwell, AD
    [J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (08) : 1009 - 1021
  • [8] The aryl hydrocarbon receptor in anticancer drug discovery: Friend or foe?
    Bradshaw, TD
    Trapani, V
    Vasselin, DA
    Westwell, AD
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (27) : 2475 - 2490
  • [9] 2-(4-aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity
    Bradshaw, TD
    Wrigley, S
    Shi, DF
    Schultz, RJ
    Paull, KD
    Stevens, MFG
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (05) : 745 - 752
  • [10] Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo
    Bradshaw, TD
    Schultz, RJ
    Paull, KD
    Kelland, L
    Wilson, A
    Garner, C
    Fiebig, HH
    Wrigley, S
    Stevens, MFG
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (04) : 421 - 429